Snapshot from Apr 21, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Anavex Life Sciences
Company

Anavex Life Sciences

Tracked across 1 events · 7 articles · First seen Feb 03, 2026 · Last active Mar 30, 2026

Sentiment
30
Attention
4
Events
1
Relationships
2
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
4 30
Business
Anavex Life Sciences Q1 2026 Earnings & Blarcamesine Updates
Anavex Life Sciences reported its Q1 fiscal 2026 financial results, showing a decrease in net loss and R&D expenses, and an increase in cash and cash equivalents. The company is progressing its clinical pipeline, particularly blarcamesine for Alzheimer's disease, despite a negative opinion from the EMA, which Anavex Life Sciences is appealing.
Feb 03, 2026 · 7 articles
Relationships (2)
Christopher U. Missling CEO ↔ Anavex Life Sciences Christopher U. Missling is the President and CEO of Anavex Life Sciences.
Wolfgang Liedtke Senior Vice President, Global Head of Neurology ↔ Anavex Life Sciences Wolfgang Liedtke is the Senior Vice President, Global Head of Neurology at Anave
NEWSDESK
Track Anavex Life Sciences live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.